Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25005258 | 0.75 | KDM4E (0.38) | SLC6A4CYP1A2KDM1AMAOBALDH1A1 | |
| SCHEMBL17147930 | 0.73 | SLC6A4 (0.53) | SLC6A4CYP1A2KDM1AMAOAMAOB | |
| SCHEMBL17785558 | 0.72 | KDM4E (0.56) | SLC6A4CYP1A2KDM1AMAOAMAOB | |
| SCHEMBL2135495 | 0.72 | SLC6A4 (0.52) | SLC6A4CYP1A2KDM1AMAOAMAOB | |
| SCHEMBL10288441 | 0.72 | SLC6A4 (0.52) | SLC6A4CYP1A2KDM1AMAOAMAOB | |
| SCHEMBL25005543 | 0.72 | ALDH1A1 (0.46) | SLC6A4CYP1A2PDGFRBPDGFRAALDH1A1 | |
| SCHEMBL2135499 | 0.72 | SLC6A4 (0.52) | SLC6A4CYP1A2KDM1AMAOAMAOB | |
| SCHEMBL30945561 | 0.71 | SLC6A4 (0.51) | SLC6A4CYP1A2KDM1AMAOAMAOB | |
| SCHEMBL2777948 | 0.71 | SLC6A4 (0.51) | SLC6A4CYP1A2KDM1AMAOAMAOB | |
| SCHEMBL5974206 | 0.70 | SLC6A4 (0.50) | SLC6A4CYP1A2KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | SLC6A4 1120/4885CYP1A2 3166/4885KDM1A 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.